Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1 Meeting Abstract
| Authors: | Jakubowiak, A. J.; Bahlis, N. J.; Raje, N. S.; Costello, C.; Dholaria, B. R.; Solh, M. M.; Levy, M. Y.; Tomasson, M. H.; Dube, H.; Damore, M. A.; Jiang, S.; Basu, C.; Skoura, A.; Chan, E. M.; Trudel, S.; Chu, M. P.; Gasparetto, C. J.; Dalovisio, A. P.; Sebag, M.; Lesokhin, A. M. |
| Abstract Title: | Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1 |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680302052 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.8014 |
| Notes: | Meeting Abstract: 8014 -- Meeting also held virtually -- Source: Wos |
